TransMedics Group And 2 Other Stocks That May Be Trading Below Estimated Value
In recent days, the U.S. stock market has experienced significant volatility, with major indices like the Dow Jones and Nasdaq Composite seeing sharp declines following President Trump's announcement of new tariffs on imports. These developments have heightened concerns about inflation and economic growth, leading investors to reassess their strategies in a shifting landscape. In such uncertain times, identifying stocks that may be trading below their estimated value can provide opportunities for investors looking to strengthen their portfolios amidst broader market fluctuations.
Name
Current Price
Fair Value (Est)
Discount (Est)
Provident Financial Services (NYSE:PFS)
$17.60
$34.70
49.3%
Dime Community Bancshares (NasdaqGS:DCOM)
$28.64
$56.84
49.6%
MINISO Group Holding (NYSE:MNSO)
$19.27
$38.44
49.9%
Berkshire Hills Bancorp (NYSE:BHLB)
$26.21
$51.54
49.2%
ACNB (NasdaqCM:ACNB)
$41.47
$82.45
49.7%
Associated Banc-Corp (NYSE:ASB)
$22.62
$44.83
49.5%
CI&T (NYSE:CINT)
$5.90
$11.68
49.5%
Hooker Furnishings (NasdaqGS:HOFT)
$10.39
$20.49
49.3%
Advanced Micro Devices (NasdaqGS:AMD)
$102.96
$203.95
49.5%
Rocket Lab USA (NasdaqCM:RKLB)
$19.34
$38.36
49.6%
Click here to see the full list of 200 stocks from our Undervalued US Stocks Based On Cash Flows screener.
Let's uncover some gems from our specialized screener.
Overview: TransMedics Group, Inc. is a commercial-stage medical technology company focused on transforming organ transplant therapy for end-stage organ failure patients globally, with a market cap of approximately $2.30 billion.
Operations: The company generates its revenue primarily from the Surgical & Medical Equipment segment, which amounted to $441.54 million.
Estimated Discount To Fair Value: 44.1%
TransMedics Group's recent earnings report shows a strong recovery, with net income of US$35.46 million for 2024, reversing a prior year's loss. The stock is trading at US$73.11, significantly below its estimated fair value of US$130.7, suggesting undervaluation based on discounted cash flow analysis. Despite legal challenges alleging misleading practices, the company's projected annual profit growth of 27% and revenue guidance between US$530 million to US$552 million for 2025 highlight potential for robust future performance.
According our earnings growth report, there's an indication that TransMedics Group might be ready to expand.
Take a closer look at TransMedics Group's balance sheet health here in our report.
Overview: AvePoint, Inc. offers a cloud-native data management software platform across various global regions, with a market cap of $3.05 billion.
Operations: The company's revenue segment is derived entirely from Software & Programming, totaling $330.48 million.
Estimated Discount To Fair Value: 18.7%
AvePoint's stock, priced at US$15.12, is undervalued against its estimated fair value of US$18.59, though not by a significant margin. The company forecasts revenue growth of 17.6% per year, surpassing the broader US market's rate of 8.3%. Despite a net loss in 2024 and expected profitability within three years, AvePoint is actively expanding through strategic acquisitions and product enhancements to strengthen its SaaS business and global presence.
Upon reviewing our latest growth report, AvePoint's projected financial performance appears quite optimistic.
Navigate through the intricacies of AvePoint with our comprehensive financial health report here.
Overview: Palomar Holdings, Inc. is a specialty insurance company that offers property and casualty insurance to individuals and businesses in the United States, with a market cap of approximately $3.70 billion.
Operations: The company generates revenue primarily through its Earthquake, Wind, and Flood Insurance Products, totaling $553.86 million.
Estimated Discount To Fair Value: 29.9%
Palomar Holdings is trading at US$141.72, significantly below its fair value estimate of US$202.05, offering an attractive valuation based on cash flows. The company's earnings grew 48.4% last year and are expected to continue growing significantly over the next three years, outpacing the broader US market's growth rate. Despite recent insider selling and a shelf registration filing for US$129 million, Palomar's revenue growth remains robust, exceeding market averages with strong financial performance in 2024.
Our earnings growth report unveils the potential for significant increases in Palomar Holdings' future results.
Delve into the full analysis health report here for a deeper understanding of Palomar Holdings.
Gain an insight into the universe of 200 Undervalued US Stocks Based On Cash Flows by clicking here.
Are any of these part of your asset mix? Tap into the analytical power of Simply Wall St's portfolio to get a 360-degree view on how they're shaping up.
Discover a world of investment opportunities with Simply Wall St's free app and access unparalleled stock analysis across all markets.
Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include NasdaqGM:TMDX NasdaqGS:AVPT and NasdaqGS:PLMR.
Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@simplywallst.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
27 minutes ago
- Yahoo
June 2025's Spotlight On Promising Penny Stocks
As the U.S. stock market experiences a rally fueled by optimism over U.S.-China trade talks and robust corporate earnings, investors are increasingly exploring diverse investment opportunities. Penny stocks, a term that may seem outdated yet remains relevant, represent shares of smaller or newer companies that can offer significant growth potential when backed by strong financial health. In this article, we will explore several penny stocks that demonstrate balance sheet strength and long-term potential, providing investors with opportunities to uncover hidden value in the market. Name Share Price Market Cap Financial Health Rating Imperial Petroleum (IMPP) $3.02 $103.93M ★★★★★★ New Horizon Aircraft (HOVR) $0.935 $29.35M ★★★★★★ Waterdrop (WDH) $1.475 $533.45M ★★★★★★ Greenland Technologies Holding (GTEC) $2.06 $35.83M ★★★★★★ WM Technology (MAPS) $1.11 $186.68M ★★★★★★ Perfect (PERF) $1.815 $184.86M ★★★★★★ Table Trac (TBTC) $4.86 $22.55M ★★★★★★ Flexible Solutions International (FSI) $4.32 $54.64M ★★★★★★ BAB (BABB) $0.8311 $6.04M ★★★★★★ Lifetime Brands (LCUT) $3.43 $76.88M ★★★★★☆ Click here to see the full list of 709 stocks from our US Penny Stocks screener. Let's review some notable picks from our screened stocks. Simply Wall St Financial Health Rating: ★★★★★★ Overview: Aldeyra Therapeutics, Inc. is a biotechnology company focused on discovering and developing therapies for immune-mediated and metabolic diseases, with a market cap of approximately $159.32 million. Operations: Aldeyra Therapeutics, Inc. does not report any revenue segments. Market Cap: $159.32M Aldeyra Therapeutics, with a market cap of US$159.32 million, is a pre-revenue biotechnology firm navigating the challenging landscape of clinical trials and regulatory approvals. Despite recent setbacks from the FDA regarding its dry eye treatment candidate reproxalap, the company achieved significant milestones in Phase 3 trials that may address previous concerns. Financially, Aldeyra maintains strong short-term liquidity with US$92.7 million in assets against liabilities and has more cash than debt, providing a runway exceeding one year. However, high volatility and ongoing losses highlight inherent risks typical for companies at this developmental stage in the biotech sector. Unlock comprehensive insights into our analysis of Aldeyra Therapeutics stock in this financial health report. Explore Aldeyra Therapeutics' analyst forecasts in our growth report. Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: Maravai LifeSciences Holdings, Inc. is a life sciences company that offers products supporting the development of drug therapies, vaccines, cell and gene therapies, and diagnostics across various global regions with a market cap of $608.64 million. Operations: The company generates revenue primarily from Nucleic Acid Production, which accounts for $179.08 million, and Biologics Safety Testing, contributing $62.78 million. Market Cap: $608.64M Maravai LifeSciences Holdings, with a market cap of US$608.64 million, faces challenges typical for penny stocks, including recent declines in sales and increased net losses. The company reported first-quarter sales of US$46.85 million, down from US$64.18 million a year prior, and a net loss of US$29.95 million compared to the previous year's US$12.08 million loss. Despite its unprofitability, Maravai has strong short-term liquidity with assets surpassing both short- and long-term liabilities and has reduced its debt-to-equity ratio over five years from 262.7% to 55.6%, indicating improved financial management amidst volatility concerns. Navigate through the intricacies of Maravai LifeSciences Holdings with our comprehensive balance sheet health report here. Assess Maravai LifeSciences Holdings' future earnings estimates with our detailed growth reports. Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: Ranpak Holdings Corp. offers product protection and end-of-line automation solutions for e-commerce and industrial supply chains across North America, Europe, and Asia, with a market cap of approximately $306.61 million. Operations: The company generates $374.8 million in revenue from its product protection and automation solutions for e-commerce and industrial supply chains. Market Cap: $306.61M Ranpak Holdings, with a market cap of US$306.61 million, exemplifies the volatility and potential of penny stocks. Despite being unprofitable with increasing losses over five years and a negative return on equity, Ranpak maintains a seasoned management team and board. The company reported first-quarter revenue growth to US$91.2 million but also faced a net loss of US$10.9 million. Recent strategic partnerships, like the one with Thalia for automated packaging systems, highlight its commitment to innovation in e-commerce fulfillment solutions while managing high debt levels and maintaining sufficient cash runway for over three years. Click to explore a detailed breakdown of our findings in Ranpak Holdings' financial health report. Understand Ranpak Holdings' earnings outlook by examining our growth report. Explore the 709 names from our US Penny Stocks screener here. Ready To Venture Into Other Investment Styles? Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ALDX MRVI and PACK. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
New York Times
31 minutes ago
- New York Times
NATO Chief Urges Members to Spend Far More on Military
The chief of NATO on Monday called on the alliance to make a 'quantum leap in our collective defense,' committing to increases in military spending that far outstrip what Britain and most other members have yet pledged. Speaking in London, Mark Rutte, NATO's secretary-general, laid bare the budget pressures that will face Britain and its European neighbors as they confront the aggression of Russia and the retrenchment of the United States. Mr. Rutte, a former prime minister of the Netherlands, is pushing for members to commit to spending 5 percent of their gross domestic product on military and defense-related activities, a target promoted by President Trump, who complains that the alliance has long unfairly burdened the United States. Mr. Rutte hopes to enshrine the new benchmark at a NATO summit meeting in The Hague on June 24 and 25. But he has yet to set a timeline for when members would be required to meet it — and the goal still seems elusive. Britain has pledged to increase military spending to 2.5 percent of gross domestic product by 2027, paid for by diverting funds from overseas aid. Prime Minister Keir Starmer has set a goal of 3 percent within a decade, though he has refused to give a more specific date without knowing where the money will come from. Ramping up to 5 percent, analysts say, would necessitate politically painful trade-offs for Britain, which is already dealing with straitened public finances. Britain currently spends 2.3 percent of its economic output on defense, more than France or Germany but less than the United States, at about 3.4 percent. Want all of The Times? Subscribe.
Yahoo
39 minutes ago
- Yahoo
Mitsubishi plans battery swapping tech for electric CVs in Tokyo
Mitsubishi Fuso Truck and Bus (MFTBC), in collaboration with Mitsubishi Motors, Ample, and Yamato Transport, is set to roll out an EV battery swapping initiative in Tokyo, Japan, by September 2025. The plan includes introducing more than 150 battery-swappable commercial electric vehicles (EVs) and creating 14 modular battery swapping stations across the city. This major move towards sustainable transportation follows a smaller pilot in Kyoto last year and will feature MFTBC's eCanter light-duty truck and Mitsubishi Motors' Minicab EV, targeting commercial delivery fleets. Yamato Transport will be the first major customer, focusing on last-mile delivery applications. Ample, a US-based battery swapping company, will provide the technology for the EV platforms and will be responsible for installing and operating the swapping stations. The Tokyo Metropolitan Environment Public Corporation is backing the project through its "Technology Development Support Project for Promoting New Energy", aligning with Japan's climate goals. Japan aims to reduce greenhouse gas emissions by 46% from 2013 levels by 2030 and achieve carbon neutrality by 2050. With the transportation sector responsible for nearly 19% of the country's CO₂ emissions in 2022, commercial fleet electrification is a strategic priority for Japan's decarbonisation efforts. The consortium in Tokyo is targeting battery swapping times of just five minutes, offering a fully automated service where drivers do not need to exit their vehicles. Ample's compact and rapidly deployable stations are a practical solution for high-utilisation fleets in dense urban areas like Tokyo. Future expansions of this initiative may include grid services, such as renewable energy storage, to further reduce greenhouse gas emissions. This initiative builds on previous collaborations, with Yamato Transport pioneering commercial EV battery swapping since 2022 and a successful pilot involving commercial delivery and battery swapping taxis in Kyoto in 2024. "Mitsubishi plans battery swapping tech for electric CVs in Tokyo" was originally created and published by Just Auto, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
